Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.58 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638947 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL60846 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL7188409 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL2695072 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL1044717 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL62052 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL418810 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL2693656 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL905578 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL60424 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102836-A1 | Amoebicidal Compositions for Contact Lens Solutions | UNIVERSITY OF THE WEST OF SCOTLAND (GB) | 2023-03-30 | — | — | US | claimed |
| WO-2021028696-A1 | AMOEBICIDAL COMPOSITIONS FOR CONTACT LENS SOLUTIONS | UNIVERSITY OF THE WEST OF SCOTLAND (GB) | 2021-02-18 | — | — | WO | claimed |
| US-7465716-B2 | Targeted drug delivery with a hyaluronan ligand | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-16 | — | — | US | claimed |
| EP-1233754-A4 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | UNIV CALIFORNIA (US) | 2006-06-07 | — | — | EP | claimed |
| JP-2004511426-A | — | — | 2004-04-15 | — | — | JP | claimed |
| US-20030166602-A1 | A delivery vehicle low molecular weight hyaluronan ligand, glycosaminoglycan ligand for binding to antigen, with antitumor agents, or anticancer agents | SZOKA FRANCIS C (US) | 2003-09-04 | — | — | US | claimed |
| WO-2001082899-A9 | CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES | MBT MUNICH BIOTECHNOLOGY AG (DE) | 2003-05-08 | — | — | WO | claimed |
| US-20030083313-A1 | Treatment of breast cancer with a liposome mixture comprising an antineoplastic alkylphospholipid and water- or lipid-soluble antiestrogen agents | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1278512-A2 | CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES | MBT Munich Biotechnology AG (DE) | 2003-01-29 | — | — | EP | claimed |
| EP-1135193-B1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX DELBRUECK CENTRUM (DE) | 2002-10-30 | — | — | EP | claimed |
| US-20020131995-A1 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | CALIFORNIA, UNIVERSITY OF THE, REGENTS OF, THE | 2002-09-19 | — | — | US | claimed |
| EP-1233754-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | The Regents of The University of California (US) | 2002-08-28 | — | — | EP | claimed |
| US-20020034537-A1 | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | MEDIGENE ONCOLOGY GMBH (DE) | 2002-03-21 | — | — | US | claimed |
| WO-2001082899-A2 | CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES | MBT MUNICH BIOTECHNOLOGY AG (DE) | 2001-11-08 | — | — | WO | claimed |
| EP-1135193-A1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2001-09-26 | — | — | EP | claimed |
| WO-2001039815-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2000033917-A1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2000-06-15 | — | — | WO | claimed |
| WO-2026099586-A1 | DRY POWDER FORMULATIONS | NANOPHARM LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| EP-0230575-A2 | Medicament active against tumours, containing hexadecylphosphocholine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-08-05 | — | — | EP | disclosed |
| WO-1987003480-A2 | MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) | 1987-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102836-A1 | Amoebicidal Compositions for Contact Lens Solutions | APH1B, PHOSPHO1, UACA | FDPS 4180/4885GGPS1 2889/4885SMPD1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.